Company news

NovoCure Limited news in 2025

NovoCure Limited's news releases, calls and decks from 2025, newest first.

View company

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

December 21, 2025

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

November 30, 2025

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

November 25, 2025

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

November 11, 2025

Novocure Reports Third Quarter 2025 Financial Results

October 29, 2025

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

October 14, 2025

Novocure to Report Third Quarter 2025 Financial Results

September 30, 2025

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

September 28, 2025

Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

September 14, 2025

Novocure Announces Upcoming Investor Events

August 27, 2025

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

August 24, 2025

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

August 19, 2025

Novocure Reports Second Quarter 2025 Financial Results

July 23, 2025

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

June 30, 2025

Novocure to Report Second Quarter 2025 Financial Results

June 29, 2025

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 30, 2025

Novocure Reports First Quarter 2025 Financial Results

April 23, 2025

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

April 22, 2025

Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

April 21, 2025

Novocure to Report First Quarter 2025 Financial Results

March 31, 2025

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

March 3, 2025

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

February 26, 2025

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

January 21, 2025

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

January 12, 2025

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

January 2, 2025

Calls in 2025

Decks in 2025